Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03602079 |
Recruitment Status :
Completed
First Posted : July 26, 2018
Last Update Posted : August 3, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HER2-positive Breast Cancer HER2 Gene Mutation HER-2 Gene Amplification HER2 Positive Gastric Cancer Salivary Gland Cancer Salivary Gland Tumor Salivary Gland Carcinoma Salivary Gland Neoplasms Lung Cancer Colo-rectal Cancer Rare Diseases Solid Tumor Recurrent Gastric Cancer Recurrent Colon Cancer Recurrent Breast Cancer Head and Neck Cancer Head and Neck Carcinoma Bladder Cancer Cervical Cancer Liver Cancer Bile Duct Cancer Urologic Cancer Pancreatic Cancer Prostate Cancer Recurrent Prostate Cancer Rectal Cancer Recurrent Ovarian Carcinoma Recurrent Renal Cell Cancer Rectal Cancer Stage II Rectal Cancer Stage I Rectal Cancer Stage III Skin Cancer Mouth Cancer Lip Cancer Stage I Tongue Cancer Breast Neoplasm Malignant Primary Larynx Cancer Tonsil Cancer Palate Cancer Mucoepidermoid Carcinoma Primary Peritoneal Carcinoma Mucinous Adenocarcinoma Gastric Mucinous Breast Cancer Recurrent Cholangiocarcinoma | Drug: A166 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 49 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies |
Actual Study Start Date : | July 16, 2018 |
Actual Primary Completion Date : | January 12, 2022 |
Actual Study Completion Date : | January 12, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Phase I: Dose Escalation
Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
|
Drug: A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells. |
Experimental: Phase II: • Cohort 1
HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
|
Drug: A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells. |
Experimental: Phase II: • Cohort 2
HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
|
Drug: A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells. |
Experimental: Phase II: • Cohort 3
HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
|
Drug: A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells. |
Experimental: Phase II: • Cohort 4
All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
|
Drug: A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells. |
- Phase I: Maximum Tolerated Dose [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]Number of patients with dose limiting toxicities
- Phase I: Number of patients with Dose Limiting Toxicities [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
- Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. [ Time Frame: Every 3 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
- Phase I: Number of participants who developed measurable anti-drug antibodies [ Time Frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
- Phase I Maximum observed serum or plasma concentration (Cmax). [ Time Frame: 84 Days from date of first dose ]
- Phase I Clearance (CL). [ Time Frame: 84 Days from date of first dose ]
- Phase I Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-∞]). [ Time Frame: 84 Days from date of first dose ]
- Phase I Terminal phase elimination half life (t½). [ Time Frame: 84 Days from date of first dose ]
- Phase I Volume of distribution at terminal phase (Vz). [ Time Frame: 84 Days from date of first dose ]
- Phase I Volume of distribution at steady state (Vss). [ Time Frame: 84 Days from date of first dose ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Phase I
Patients must meet the following criteria for inclusion into the study:
- Patients must be able to provide documented voluntary informed consent.
- Male or female patient ≥ 18 years.
- Histologically documented, incurable, locally advanced or metastatic cancer.
- Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of ≥ 1+ determined by validated IHC.
- Patients should have no available therapy likely to convey clinical benefit.
- Granulocyte count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL.
- Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
- Creatinine clearance ≥ 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.
- ECOG Performance Status ≤ 1.
- Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
- Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
Exclusion Criteria:
Phase I:
- Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
- History of Grade ≥ 3 hypersensitivity reaction to trastuzumab.
- History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued.
- Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.
- Require supplemental oxygen for daily activities.
- Documented Grade ≥ 2 peripheral neuropathy.
- Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug.
- Any experimental therapy within 4 weeks of first infusion of study drug.
- Any major surgical procedure within 4 weeks of first infusion of study drug.
- Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded.
- Have known prior positive test results for human immunodeficiency virus.
- Uncontrolled hypertension or diabetes.
- Pregnancy or lactation.
- Resting corrected QT interval (QTc) > 470 ms at baseline.
- Left ventricular ejection fraction (LVEF) < 45% determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.
- Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03602079
United States, Florida | |
Florida Cancer Specialists & Research Institute | |
Sarasota, Florida, United States, 34232 | |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center Cancer Center | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Karmanos Cancer Institute | |
Detroit, Michigan, United States, 48201 | |
United States, New York | |
Clinical Research Alliance, Inc. | |
Lake Success, New York, United States, 11042 | |
United States, Oklahoma | |
Stephenson Cancer Center | |
Oklahoma City, Oklahoma, United States, 73104 | |
United States, Oregon | |
Providence Cancer Institute | |
Portland, Oregon, United States, 97213 | |
United States, Texas | |
Mary Crowley Cancer Research Centers - Medical City | |
Dallas, Texas, United States, 75230 | |
The University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
South Texas Accelerated Research Therapeutics, LLC (START) | |
San Antonio, Texas, United States, 78229 | |
United States, Virginia | |
Virginia Cancer Specialist | |
Fairfax, Virginia, United States, 22031 |
Study Chair: | Jordi Rodon Ahnert, MD, PhD | MD Anderson |
Responsible Party: | Klus Pharma Inc. |
ClinicalTrials.gov Identifier: | NCT03602079 |
Other Study ID Numbers: |
KlusPharma |
First Posted: | July 26, 2018 Key Record Dates |
Last Update Posted: | August 3, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Neoplasms Breast Neoplasms Prostatic Neoplasms Stomach Neoplasms Rectal Neoplasms Cholangiocarcinoma Carcinoma, Renal Cell Salivary Gland Neoplasms Bile Duct Neoplasms Carcinoma, Mucoepidermoid Mucoepidermoid Tumor Tongue Neoplasms Adenocarcinoma, Mucinous Cystadenocarcinoma |
Laryngeal Neoplasms Urologic Neoplasms Mouth Neoplasms Lip Neoplasms Tonsillar Neoplasms Recurrence Rare Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms by Site Breast Diseases Skin Diseases Disease Attributes Pathologic Processes Genital Neoplasms, Male |